SUPRIYA LIFESCIENCE share price has zoomed 4% and is presently trading at Rs 579.3.
Meanwhile, the BSE HEALTHCARE index is at 42,998.1 (down 1.0%).
Among the top gainers in the BSE HEALTHCARE index today are CAPLIN POINT (up 3.1%) and MAX HEALTHCARE INSTITUTE (up 2.1%).
Glenmark Pharma (down 3.5%) and Dr. Reddys (down 3.2%) are among the top losers today.
Over the last one year, SUPRIYA LIFESCIENCE has moved up from Rs 242.6 to Rs 579.3, registering a gain of Rs 336.7 (up 138.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,318.2 to 42,998.1, registering a gain of 57.4% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 225.9%), Glenmark Pharma (up 120.2%) and SUVEN PHARMACEUTICALS (up 118.7%).
Don't Miss: Key Information for Long-term Investors
The BSE Sensex is at 79,893.7 (down 0.1%).
The top losers among the BSE Sensex today are Tata Motors (down 3.7%) and Maruti Suzuki (down 1.9%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.
In the meantime, NSE Nifty is at 24,285.9 (down 0.2%). Tata Motors and IOC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,049.1 to 79,893.7, registering a gain of 15,844.7 points (up 24.7%).
SUPRIYA LIFESCIENCE net profit grew 93.2% YoY to Rs 461 million for the quarter ended September 2024, compared to a profit of Rs 239 million a year ago. Net sales rose 18.6% to Rs 1,661 million during the period as against Rs 1,401 million in July-September 2023.
For the year ended March 2024, SUPRIYA LIFESCIENCE reported 32.6% increase in net profit to Rs 1,191 million compared to net profit of Rs 899 million during FY23. Revenue of the company grew 21.8% to Rs 4,938 million during FY24.
The current Price to earnings ratio of SUPRIYA LIFESCIENCE , based on rolling 12 month earnings, stands at 29.6.
Equitymaster requests your view! Post a comment on "SUPRIYA LIFESCIENCE Gains 4%; BSE HEALTHCARE Index Down 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!